

Estimate change

TP change

Rating change



Bloomberg	TELX IN
Equity Shares (m)	62
M.Cap.(INRb)/(USDb)	230.3 / 2.4
52-Week Range (INR)	6440 / 3558
1, 6, 12 Rel. Per (%)	-11/-27/-36
12M Avg Val (INR M)	1533
Free float (%)	56.1

Financials & Valuations (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	37.6	41.7	45.2
EBIT Margin (%)	20.0	21.6	22.5
PAT	6.3	8.2	9.2
EPS (INR)	100.9	131.3	148.4
EPS Gr. (%)	(19.9)	30.1	13.1
BV/Sh. (INR)	488.3	544.6	618.0

Ratios

RoE (%)	21.3	25.4	25.5
RoCE (%)	15.5	17.1	17.6
Payout (%)	74.3	60.0	60.0

Valuations

P/E (x)	36.6	28.2	24.9
P/BV (x)	7.6	6.8	6.0
EV/EBITDA (x)	25.3	21.4	18.4
Div Yield (%)	2.0	2.1	2.4

Shareholding pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	43.9	43.9	43.9
DII	11.4	12.3	8.6
FII	11.1	8.6	12.7
Others	33.6	35.2	34.8

FII Includes depository receipts

CMP: INR3,697

TP: INR3,100 (-16%)

Sell

Vertical recovery remains uneven

Transportation vertical remains soft; margins disappoint

- Tata Elxsi (TELX) reported revenue of USD108m in 1QFY27, up 1.3% QoQ in CC terms, broadly in line with our estimate of 1.2% QoQ CC. Growth was led by Media and Communication/Others, which grew 2.9%/21% QoQ CC, whereas HLS/Transportation declined 0.3%/0.4% QoQ CC. EBIT margin was 19% (down 330bp QoQ), below our estimate of 21.5%. Adj. PAT declined 22.6% QoQ and rose 18.2% YoY to INR1,706m (below our est. of INR2,027m).
- For 1QFY27, revenue/EBIT/adj. PAT grew 14.5%/19.2%/18.2 YoY in INR terms. We expect revenue/EBIT/adj. PAT to grow 12%/18.1%/21.7% YoY in 2QFY27. We value TELX at 21x FY28E EPS (earlier 22x), resulting in a revised TP of INR3,100. We reiterate our Sell rating.

Our view: Current valuation leaves limited room for disappointment

- **1Q does little to change the broader growth picture:** Revenue grew 1.3% QoQ CC, broadly in line with expectations, but the improvement was largely driven by Media & Communications, while Transportation and Healthcare remained weak. **We believe meaningful growth will require a recovery in the larger Transportation business (~55% of revenue),** where spending remains cautious, particularly across Europe.
- **Margins came in well below expectations:** EBIT margin contracted to 19%, below our estimate of 21.5%. Management attributed this to ~150bp of one-off costs (deal transitions, a customer-specific Chapter 11 provision, and retention costs), ~220-230bp of higher onsite delivery and subcontractor costs tied to H-1B visa constraints, and AI infra investments.
- **A company-wide wage hike in 2Q will further offset any near-term unwind of these costs.** We believe recovery could remain gradual, given the uneven demand environment and the need to continue investing in talent and capabilities.
- **Transportation recovery remains the key monitorable:** Transportation, the company's largest vertical, declined this quarter, reflecting continued weakness in automotive engineering spends. While Media & Communications can support growth in the near term, we do not believe it will be sufficient to drive a sustained acceleration without a broader improvement in Transportation and Healthcare.
- **Valuation continues to discount a stronger recovery than what we see:** We believe that revenue recovery remains concentrated in a few pockets, while Transportation demand has yet to turn and margins remain below historical levels. **At 28x/24x FY27E/FY28E consensus P/E, we believe the current valuation leaves limited room for disappointment.** We would look for broader-based growth across verticals and a more sustained margin recovery before turning more constructive on the stock.

Valuations and changes to our estimates

- We lower our FY27/FY28 EPS estimates by ~5%/~1%, reflecting weaker-than-expected margin performance in 1Q and a slower recovery in the Transportation business. While some of the margin headwinds are one-off in nature, we expect margin recovery to remain gradual amid continued investments, wage hikes in 2Q, and an uneven demand environment. We continue to model USD revenue CAGR of ~5.5% over FY26–28. We value TELX at 21x FY28E EPS (earlier 22x), resulting in a revised TP of INR3,100. We reiterate our Sell rating.

Revenue in line with our estimates and miss on margins; Media & Comms. lead growth

- USD revenue came in at USD108m, up 1.3% QoQ in CC terms, broadly in line with our estimate of 1.2% QoQ CC growth.
- Growth was led by Media and Communication/Others, which grew 2.9%/21% QoQ CC, whereas HLS/Transportation declined 0.3%/0.4% QoQ CC.
- In terms of geography, growth was driven solely by the Americas, which rose 8.6% QoQ in USD terms, while Europe/India/RoW declined 3.1%/3.4%/13.5%, respectively.
- EBIT margin was 19% (down 330bp QoQ), below our estimate of 21.5%.
- Adj. PAT declined 22.6% QoQ and rose 18.2% YoY to INR1,706m (below our est. of INR2,027m).
- The net headcount decreased by 204 employees to 11,336 (down 1.8% QoQ) in 1QFY27. Attrition (LTM) increased by 20bp QoQ to 16%.

Key highlights from the management commentary

- Management flagged a challenging global environment, with continued softness in Germany/Continental Europe impacting the automotive vertical, while calling out visa-related cost pressures (H-1B) in the US as an industry-wide constraint.
- Demand trends were mixed across verticals - Transportation and Media & Communications saw healthy traction on the back of large deal ramp-ups, while Healthcare demand remained muted, with delayed deal closures from key clients.
- Large consolidation deals in Media & Telecom continued to ramp up, with the company benefiting as an incumbent vendor in client M&A transactions, gaining access to a wider project pool.
- Adoption remains measured and calibrated, particularly in mission-critical industries like automotive and healthcare, given large, complex, multi-year legacy codebases.
- The Neuron platform helped a European telecom client (Sky) transition to zero-touch network operations, delivering 30-70% efficiency gains across parameters.
- Management retained its FY27 growth aspiration of high single digits, contingent on a recovery in the Healthcare vertical.

Valuation and view

- We lower our FY27/FY28 EPS estimates by ~5%/~1%, reflecting weaker-than-expected margin performance in 1Q and a slower recovery in the Transportation business. While some of the margin headwinds are one-off in nature, we expect margin recovery to remain gradual amid continued investments, wage hikes in 2Q, and an uneven demand environment. We continue to model USD revenue CAGR of ~5.5% over FY26–28. We value TELX at 21x FY28E EPS (earlier 22x), resulting in a revised TP of INR3,100. We reiterate our Sell rating.

Exhibit 1: Vertical-wise performance (QoQ, %)

	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Transportation	2.0	6.4	3.1	9.8	4.8	8.4	-3.3	-9.3	5.2	-2.0	5.7	1.1	-3.0
Media and Communications	0.3	-0.4	0.8	-11.7	1.1	-1.9	-0.2	-6.6	-3.7	4.5	-2.0	6.9	0.9
Healthcare and Life Sciences	3.6	3.2	4.4	-10.8	-4.5	-10.5	0.5	2.9	-5.5	-4.1	-5.7	-12.5	-2.3

Source: Company, MOFSL

Exhibit 2: Region-wise performance (QoQ, %)

	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Europe	7.0	10.2	4.0	-1.4	7.0	3.9	-7.7	-11.3	3.9	-1.7	10.7	4.1	-3.1
Americas	-1.4	1.5	-3.0	-4.6	-4.3	-7.7	-0.5	-6.3	-2.0	5.4	3.1	-8.1	8.6
India	-0.2	-6.0	8.7	4.5	4.0	9.7	0.7	9.2	-11.9	-3.7	-10.5	2.3	-3.4
RoW	-7.2	-4.7	19.5	9.5	5.5	31.1	9.3	-7.5	15.0	2.3	-11.5	21.4	-13.5

Source: Company, MOFSL

Quarterly Performance

Y/E March	FY26				FY27E				FY26	FY27E	(INR M)	
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			Est. 1QFY27	Var. (% / bp)
Revenue (USD m)	105	105	107	109	108	109	111	114	426	442	109	-1.1
QoQ (%)	-0.3	0.4	1.8	1.7	-1.0	1.0	2.3	2.0			0.2	-115bp
Revenue (INR m)	8,921	9,181	9,535	9,938	10,211	10,283	10,519	10,729	37,575	41,742	10,330	-1.1
YoY (%)	-3.7	-3.9	1.5	9.4	14.5	12.0	10.3	8.0	0.8	11.1	15.8	-133bp
GPM (%)	20.9	21.1	23.3	24.6	21.2	21.7	25.0	27.0	22.5	23.8	23.8	-265bp
SGA (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0bp
EBITDA	1,867	1,933	2,222	2,446	2,160	2,231	2,630	2,897	8,469	9,918	2,458	-12.1
EBITDA Margin (%)	20.9	21.1	23.3	24.6	21.2	21.7	25.0	27.0	22.5	23.8	23.8	-265bp
EBIT	1,625	1,699	1,994	2,213	1,937	2,007	2,398	2,661	7,531	9,004	2,221	-12.8
EBIT Margin (%)	18.2	18.5	20.9	22.3	19.0	19.5	22.8	24.8	20.0	21.6	21.5	-253bp
Other income	339	448	425	465	387	473	484	494	1,677	1,838	465	-16.7
ETR (%)	26.5	27.9	26.0	17.7	26.6	24.0	24.0	24.0	24.1	24.6	24.5	210bp
Adj PAT	1,444	1,548	1,791	2,204	1,706	1,885	2,190	2,397	6,987	8,179	2,027	-15.9
Exceptional items	0.0	0.0	702	0.0	0.0	0.0	0	0.0	702	0	0.0	
PAT	1,444	1,548	1,089	2,204	1,706	1,885	2,190	2,397	6,285	8,179	2,027	-15.9
QoQ (%)	-16.3	7.2	-29.7	102.4	-22.6	10.5	16.2	9.4			-8.0	
YoY (%)	-21.6	-32.5	-45.3	27.8	18.2	21.7	101.1	8.8	-11.0	17.1	40.4	
EPS (INR)	23.2	24.9	17.5	35.4	27.4	30.3	35.2	38.5	100.9	131.3	32.5	-15.8

Key Performance Indicators

Y/E March	FY26				FY27	FY26
	1Q	2Q	3Q	4Q	1Q	
Revenue (QoQ CC %)	-3.9	1.0	3.2	0.9	1.3	
Margins (%)						
Gross Margin	20.9	21.1	23.3	24.6	21.2	22.5
EBIT Margin	18.2	18.5	20.9	22.3	19.0	20.0
Net Margin	16.2	16.9	18.8	22.2	16.7	18.6
Operating metrics						
Headcount	12,127	11,951	11,594	11,590	11,336	12,127
Attrition (%)	15.0	15.4	15.6	15.8	16.0	15.0
Key Geographies (YoY %)						
Europe	-11.7	-16.4	0.4	17.8	9.9	-3.4
USA	-15.7	-3.8	-0.3	-2.2	8.4	-5.8



Highlights from the management commentary

1QFY27 performance and demand outlook

- Management flagged a challenging global environment, with continued softness in Germany/Continental Europe impacting the automotive vertical, while calling out visa-related cost pressures (H-1B) in the US as an industry-wide constraint.
- Demand trends were mixed across verticals - Transportation and Media & Communications saw healthy traction on the back of large deal ramp-ups, while Healthcare demand remained muted, with delayed deal closures from key clients.
- Large consolidation deals in Media & Telecom continued to ramp up, with the company benefiting as an incumbent vendor in client M&A transactions, gaining access to a wider project pool.
- Adoption remains measured and calibrated, particularly in mission-critical industries like automotive and healthcare, given large, complex, multi-year legacy codebases.
- Neuron platform helped a European telecom client (Sky) transition to zero-touch network operations, delivering 30-70% efficiency gains across parameters.
- Management retained its FY27 growth aspiration of high single digits, contingent on a recovery in the Healthcare vertical.
- Revenue was near flat, down 0.3% QoQ in CC, reflecting a muted global healthcare spending environment and staggered deal awards.
- Healthcare deal pipeline remains active, but paperwork/closure delays pushed expected wins beyond 1Q.
- The company won a strategic deal with a global medtech company for its AI-led material intelligence platform. It secured large automotive OEM, off-road and aerospace engagements in Transportation.
- **Transportation:** It contributes >55% of segment revenue. The segment grew 6.7% YoY in CC and 13.3% YoY in actual currency, led by large OEM engagements and strategic wins in off-road and aerospace.
- OEM mix now stands at 78% of automotive revenue, reflecting continued pivot toward OEM clients; Germany/Europe remain soft, but the US and APAC delivered strong recovery.
- **Healthcare & Life Sciences:** Revenue was near flat, down 0.3% QoQ in CC, reflecting a muted global healthcare spending environment and staggered deal awards. It contributes less than 10% of total revenue. The company continues to invest in platform capabilities and AI-enabled offerings, expecting the vertical to return to growth within FY27.
- **Media & Communication:** It delivered the strongest growth among verticals: +4.7% QoQ / +22.2% YoY in actual currency, and +2.9% QoQ / +11.5% YoY in CC. Management expects growth momentum to sustain over the next 2-3 quarters on the back of large pipeline deals in media/telecom consolidation.
- **Americas:** It outperformed across verticals, led by new deal wins and ramp-ups. Onshore delivery costs (forward teams, subcontractors) were elevated to support transition and mitigate visa-related delays.
- **Europe:** It continues to be the largest geography for Transportation (>40% of vertical revenue), but remains under pressure due to OEM softness, particularly in Germany.
- Management is adopting a wait-and-watch approach on Continental Europe, given the macro uncertainty, though existing deal execution remains unaffected.
- Management views AI adoption as domain-led rather than technology-led, with the Neuron and Vitro platforms enabling customer-facing transformation

(cybersecurity, autonomous operations, SDLC efficiency) rather than pure cost plays.

- Onsite-offshore mix shifted marginally to ~74:26 from ~75:25, driven by short-term onsite ramp-up needs. The company reiterated that its structural target of ~90:10 offshore-heavy delivery remains unchanged.
- One customer's Chapter 11 filing led to a one-time higher provisioning during the quarter, factored into the margin bridge.
- Utilization stood at ~75%, providing headroom before aggressive fresher hiring resumes; fresher additions were modest (~100-150 in the quarter) versus the prior year.
- Attrition stands at ~16%; the company is prioritizing retention of niche/critical talent (AI, domain-specific skills) over broad-based lateral hiring.

Margin outlook

- EBITDA came in at INR2.16b, +15.7% YoY, with margin at 21.2%; EBIT margin contracted ~330bp QoQ, reflecting a mix of one-off costs and planned investments.
- Margin walk: ~40-50bp benefit from cross-currency gains, offset by ~150bp of one-off/transition-related costs (large deal transitions, select employee retention, a customer-specific Chapter 11 provision, and upfronting of annual costs) and ~220-230bp toward strategic investments (onsite delivery ramp-up, subcontractor costs due to US visa constraints, and specialized talent/AI infrastructure).
- Management expects the one-off cost bucket to largely unwind over the next 1-2 quarters, while investment-related costs should normalize gradually as ramp-ups stabilize and work shifts back offshore.
- A company-wide wage hike is planned in 2QFY27 (versus staggered hikes last year), which will partly offset the margin recovery from one-offs rolling off. A sequential margin improvement is expected through FY27 as revenue scales and hikes get absorbed.

Valuation and view


- We lower our FY27/FY28 EPS estimates by ~5%/~1%, reflecting weaker-than-expected margin performance in 1Q and a slower recovery in the Transportation business. While some of the margin headwinds are one-off in nature, we expect margin recovery to remain gradual amid continued investments, wage hikes in 2Q, and an uneven demand environment. We continue to model USD revenue CAGR of ~5.5% over FY26–28. We value TELX at 21x FY28E EPS (earlier 22x), resulting in a revised TP of INR3,100. We reiterate our Sell rating.

Exhibit 3: Summary of our revised estimates


	Revised		Earlier		Change	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
INR/USD	94.5	95.0	94.5	95.0	0.0%	0.0%
USD Revenue (m)	442	475	447	488	-1.2%	-2.5%
Growth (%)	3.69	7.6	4.9	9.1	-120bps	-150bps
EBIT margin (%)	21.6	22.5	22.6	23.7	-110bps	-120bps
Adj. PAT (INR b)	8,179	9,249	8,655	9,339	-5.5%	-1.0%
Adj. EPS	131.3	148.4	138.9	149.9	-5.5%	-1.0%

Source: MOFSL


Story in charts

Exhibit 4: Revenue increased to 1.3% QoQ CC growth



Source: Company, MOFSL

Exhibit 5: EBIT margin contracted 330bp QoQ



Source: Company, MOFSL

Exhibit 6: Transportation decreased to 1.6% QoQ growth



Source: Company, MOFSL

Exhibit 7: Media and Comms has shown significant recovery


Source: Company, MOFSL

Exhibit 8: HLS decreased to a 22.7% YoY decline


Source: Company, MOFSL

Exhibit 9: T&M remained stable


Source: Company, MOFSL

Operating metrics

Exhibit 10: Operating metrics

	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Verticals (%)									
Transportation	52.8	55.7	55.0	53.4	55.8	54.7	56.6	56.3	55.3
Media and Communications	33.3	31.8	32.4	32.4	31.0	32.4	31.1	32.7	33.4
Healthcare and Life Sciences	13.2	11.5	11.8	13.0	12.2	11.7	10.8	9.3	9.2
Geographies (%)									
Europe	42.2	42.7	40.4	37.9	39.5	38.7	42.1	43.1	42.2
Americas	33.7	30.3	30.9	30.6	30.1	31.6	32.0	28.9	31.7
India	17.6	18.8	19.4	22.4	19.8	19.0	16.7	16.8	16.4
Row	6.5	8.3	9.3	9.1	10.5	10.7	9.3	11.1	9.7
Segments (%)									
Software Development and Services	97.0	97.1	97.5	96.3	97.3	96.9	97.2	97.1	96.9
System Integration and Support	3.0	2.9	2.5	3.7	2.7	3.1	2.8	2.9	3.1
Project Type (%)									
Fixed Price	50.9	50.5	51.9	50.7	51.9	56.3	54.4	58.9	57.8
Time and Material	49.1	49.0	48.1	49.3	48.1	43.7	45.6	41.1	42.2
Revenue Mix (%)									
Onsite	27.2	25.3	25.8	25.9	26.9	26.1	27.0	25.0	25.9
Offsite	72.8	74.7	74.2	74.1	73.1	73.9	73.0	75.0	74.1
QoQ growth (CC, %)									
Transportation	5.3	4.4	0.5	-9.7	0.0	-0.5	7.3	0.2	-0.4
Media and Communications	0.5	-2.6	0.4	-6.3	-5.5	3.7	-1.3	5.6	2.9
Healthcare and Life Sciences	-4.3	-11.2	1.1	3.5	-6.7	-4.6	-4.3	-13.1	-0.3
Client Metrics (%)									
Top 5 Clients	47.2	45.1	44.8	46.2	44.7	44.2	49.4	49.6	49.2
Top 10 Clients	58.0	55.6	54.2	55.9	54.6	54.7	59.4	58.8	59.7
Employee Metrics (%)									
Total Employees	13,142	12,793	12,878	12,414	12,127	11,951	11,594	11,590	11,336
Attrition (%)	12.3	12.5	12.4	13.3	15.0	15.4	15.6	15.8	16.0

Source: Company, MOFSL

Financials and valuations

Consolidated - Income Statement

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	24,708	31,447	35,521	37,290	37,575	41,742	45,157
Change (%)	35.3	27.3	13.0	5.0	0.8	11.1	8.2
Employees Cost	17,050	21,834	25,057	27,561	29,106	31,824	33,750
Total Expenditure	17,050	21,834	25,057	27,561	29,106	31,824	33,750
% of Sales	69.0	69.4	70.5	73.9	77.5	76.2	74.7
Gross Profit	7,658	9,613	10,464	9,730	8,469	9,918	11,407
SG&A	0	0	0	0	0	0	0
EBITDA	7,658	9,613	10,464	9,730	8,469	9,918	11,407
% of Sales	31.0	30.6	29.5	26.1	22.5	23.8	25.3
Depreciation	557	814	994	1,049	938	914	1,264
EBIT	7,101	8,799	9,470	8,681	7,531	9,004	10,143
% of Sales	28.7	28.0	26.7	23.3	20.0	21.6	22.5
Other Income	351	576	1,017	1,603	1,677	1,838	2,077
PBT	7,452	9,375	10,487	10,284	9,209	10,841	12,220
Total Tax	1,958	1,823	2,564	2,435	2,221	2,663	2,971
Tax Rate (%)	26.3	19.4	24.5	23.7	24.1	24.6	24.3
Adjusted PAT	5,494	7,552	7,922	7,850	6,987	8,179	9,249
Change (%)	49.2	37.5	4.9	-0.9	-11.0	17.1	13.1
Margin (%)	22.2	24.0	22.3	21.1	18.6	19.6	20.5
Minority Interest/Exceptional Items	0	0	0	0	702	0	0
Reported PAT	5,494	7,552	7,922	7,850	6,285	8,179	9,249

Consolidated - Balance Sheet

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	623	623	623	623	623	623	623
Total Reserves	15,386	20,235	24,434	27,977	29,790	33,296	37,872
Net Worth	16,009	20,858	25,057	28,600	30,413	33,919	38,494
Minority Interest	0	0	0	0	0	0	0
Borrowings	1,183	1,537	1,812	1,393	1,037	1,037	1,037
Other Long term liabilities	398	455	542	568	605	635	687
Capital Employed	17,590	22,849	27,410	30,560	32,055	35,591	40,219
Net Fixed Assets	2,512	3,174	3,825	3,092	2,542	2,880	2,970
Goodwill	203	162	134	88	50	50	50
Capital WIP	221	70	22	16	0	0	0
Other Assets	1,799	1,094	2,521	4,686	7,351	8,377	9,044
Curr. Assets, Loans&Adv.	16,957	23,135	25,367	27,975	29,681	31,209	35,247
Account Receivables	6,728	9,764	9,716	9,715	10,794	10,293	11,135
Cash and Bank Balance	1,511	1,339	1,332	1,353	1,945	3,711	6,709
Current Investments	8,294	11,051	12,806	14,992	14,990	15,055	15,077
Other Current Assets	424	981	1,513	1,915	1,953	2,150	2,326
Curr. Liability & Prov.	4,102	4,786	4,459	5,297	7,570	6,923	7,093
Account Payables	843	1,032	856	1,230	1,203	1,205	1,278
Other Current Liabilities	3,133	3,498	3,218	3,575	5,044	4,396	4,493
Provisions	126	256	385	492	1,323	1,323	1,323
Net Current Assets	12,855	18,349	20,908	22,678	22,112	24,286	28,155
Appl. of Funds	17,590	22,849	27,410	30,560	32,055	35,593	40,220

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic EPS (INR)	88.3	121.3	127.2	126.0	100.9	131.3	148.4
Cash EPS	97.2	134.3	143.2	142.8	115.9	145.9	168.7
BV/Share	257.1	334.9	402.3	459.2	488.3	544.6	618.0
DPS	42.5	60.6	70.0	75.0	75.0	78.8	89.1
Payout (%)	48.2	50.0	55.0	59.5	74.3	60.0	60.0
Valuation (x)							
P/E	41.9	30.5	29.1	29.3	36.6	28.2	24.9
Cash P/E	38.0	27.5	25.8	25.9	31.9	25.3	21.9
P/BV	14.4	11.0	9.2	8.1	7.6	6.8	6.0
EV/Sales	9.0	7.0	6.1	5.8	5.7	5.1	4.6
EV/EBITDA	28.9	22.8	20.8	22.1	25.3	21.4	18.4
Dividend Yield (%)	1.1	1.6	1.9	2.0	2.0	2.1	2.4
Return Ratios (%)							
RoE	37.2	41.0	34.5	29.3	21.3	25.4	25.5
RoCE	27.1	29.0	24.3	19.8	15.5	17.1	17.6

Consolidated - Cash Flow Statement

(INR m)

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	7,452	9,375	10,487	10,284	8,252	10,841	12,220
Depreciation	553	814	994	1,049	938	914	1,264
Interest & Finance Charges	94	162	203	190	162	0	0
Direct Taxes Paid	-2,062	-1,848	-2,580	-2,239	-2,240	-2,158	-3,024
(Inc)/Dec in WC	-1,002	-3,097	-1,351	-242	674	-408	-871
Others	-208	-538	-741	-921	-1,145	-1,807	-2,025
CF from Operations	4,827	4,867	7,012	8,120	6,641	7,383	7,563
(Inc)/Dec in FA	-712	-637	-830	-162	-103	-1,252	-1,355
Free Cash Flow	4,116	4,230	6,182	7,959	6,537	6,131	6,209
(Pur)/Sale of Investments	-656	-1,695	-2,745	-3,741	-1,879	-1,530	-615
Others	285	313	874	820	1,257	1,838	2,077
CF from Investments	-1,083	-2,019	-2,701	-3,083	-725	-945	108
Inc/(Dec) in Debt	-271	-381	-498	-612	-659	0	0
Interest Paid	-1	-4	-7	-14	-18	0	0
Dividend Paid	-2,989	-2,647	-3,774	-4,359	-4,671	-4,673	-4,673
CF from Fin. Activity	-3,261	-3,031	-4,278	-4,986	-5,348	-4,673	-4,673
Inc/Dec of Cash	483	-183	33	51	567	1,765	2,998
Forex Adjustment	20	10	-39	-31	26	0	0
Opening Balance	1,007	1,511	1,338	1,331	1,352	1,945	3,710
Closing Balance	1,511	1,338	1,331	1,352	1,945	3,710	6,708

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.